SOURCE: Rx Safes Inc.

Rx Safes Inc.

November 12, 2015 09:21 ET

UPDATE - Rx Safes Announces Patent Acquisition

Company Strengthens Intellectual Property Protection for Rx SafeDOSE

HENDERSON, NV--(Marketwired - Nov 12, 2015) - Rx Safes, Inc. (OTC PINK: RXSFD), the developer of patented autonomous fingerprint healthcare security products announced today that it has acquired another patent that further expands the company's intellectual property portfolio, protecting its Rx SafeDOSE, Patient Controlled Analgesia pendant.

The patent inventor, Phillip Jurson, MD., a nationally renowned anesthesiologist and pain management physician, was awarded patent number 7,806,852 -- method and apparatus for patient-controlled medical therapeutics utilizing biometrics in a patient controlled administration of pain medications, with a priority date in April 2006. This patent strengthens the company's intellectual property surrounding its Rx SafeDOSE product. The patent also includes claims that cover additional control features on the pendant, which will provide an even greater level of safety for patients and allow Rx Safes the ability to corner the market for the secure patient administration of medications.

"In developing this patent, it was my intention to solve the critical problem of PCA by Proxy," indicated patent inventor, Phillip Jurson, M.D. "I am extremely encouraged that through my relationship with Rx Safes, this issue can finally be addressed in a practical manner," added Dr. Jurson.

"We are putting infusion pump manufacturers such as Hospira, Baxter, Abbott and Smiths Medical on notice that we have already developed and proven the next generation of universal PCA pendant controllers, to provide improved security and patient safety when used in conjunction with each of their respective infusion pumps in a PCA setting," commented Lorraine Yarde, CEO of Rx Safes, Inc.

There are in excess of 600,000 PCA Pendants in use in hospitals throughout the US alone, and this does not consider usage in the home or in assisted living/nursing facilities. These devices have a short operating lifespan and are typically replaced every 10 to 14 months. "This is a multi-billion dollar market and what makes our position even stronger is that we have a product ready for FDA approval that is protected by two extremely valuable patents. There have been no improvements to infusion pump pendants in decades and we view this as a key entry point because the Rx SafeDOSE uses fingerprint technology to authenticate an authorized user before medication is administered. In order for the leading pump manufacturers to utilize this technology they will be forced to look to us for the solution and we are ready and willing to open discussions," Ms. Yarde added.

The company continues to build the value of its patent portfolio in the area of medical devices incorporating our fingerprint technology. Through developing and acquiring product specific intellectual property, we strengthen our ability to protect our innovative products from competition as we continue to establish Rx Safes™ as the trusted brand in biometric products for healthcare.

About Rx Safes, Inc.

Rx Safes is an emerging leader in the personal and professional healthcare drug security market. Our products incorporate proprietary patented fingerprint technology to provide drug security solutions for use in homes and healthcare facilities. Prescription drug misuse, skyrocketing insurance and pharmaceutical treatment costs and increased regulatory pressures create an unfortunate, yet necessary opportunity for Rx Safes to expand our reach and offerings in this growing market, valued at over $50 billion annually. Annual spending on healthcare technology products exceeds $34.5 billion. In addition, the market is being driven by ongoing Government support for successful drug abuse prevention initiatives, with a financial commitment of $25.4 billion in 2015 alone. For more information, please visit www.rxdrugsafe.com

Forward-Looking Statements for RXSF:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Like us on Facebook at https://www.facebook.com/rx.drugsafe
Follow us on Twitter at https://twitter.com/RxDrugSAFE

Contact Information

  • Investor Relations Contact:

    Email: Email Contact
    Telephone: 1-844-RXSAFES Ext 4